
|Videos|December 2, 2021
Pharmacist Medication Insights: Parathyroid Hormone (Natpara) for Hypocalcemia
Author(s)Saro Arakelians, PharmD
Parathyroid hormone (Natpara) is indicated to control hypocalcemia in patients with hypoparathyroidism.
Advertisement
Shire’s parathyroid hormone (Natpara) is indicated to control hypocalcemia in patients with hypoparathyroidism.
The FDA approved Natpara in January 2015 as an adjunct to calcium and vitamin D therapy. The bioengineered replica of human parathyroid hormone is self-administered once a day by subcutaneous injection, and it is available in 4 dosage strengths: 25 mcg, 50 mcg, 75 mcg, and 100 mcg.
The most common side effects associated with Natpara include a tingling, tickling, or burning feeling on the skin, as well as headache and nausea.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
2
The Side Door We Could Close: A Pharmacy Perspective on Menopause, Access, and the Leadership Pipeline
3
CVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal
4
Study Reveals a Widening Gap Between Buprenorphine Prescribing and Dispensing
5



































































































